Opportunity with a wider range of risks
At the start of 2026, industry discussions suggested greater interest in growth, partnerships, acquisitions, and pipeline investment after a defensive 2025. This article’s May 2026 view was cautiously positive, while recognizing uncertainty around regulatory leadership, pricing policy, tariffs, conflict, and operating costs.
Those observations describe the market at publication, rather than a prediction of today’s conditions.
Strengthen the operating fundamentals
Biopharma leaders can prepare by reassessing portfolio assumptions, testing development timelines, and identifying dependencies across clinical, regulatory, manufacturing, and commercial work. Build contingency options before a disruption narrows the available choices.
A resilient operating model does not require executives to forecast every policy or market change correctly. It requires clear priorities, visible risks, cross-functional alignment, and enough flexibility to adapt. Improving those fundamentals helps organizations protect progress while making informed use of new growth opportunities.